Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications. This report studies the current as well as future scenario of the diabetes diagnostic devices and drugs market globally.
The diabetes diagnostic devices and drugs market has been segmented based on devices and drugs available for the treatment the disease. Based on device type, the market is segmented into diabetes diagnostic devices and insulin delivery devices. Diabetes diagnostic devices include analog blood meter, test strips, lancets and lancing devices, continuous glucose monitoring devices and others. The insulin delivery devices segment include insulin syringes, insulin pens, insulin pumps and insulin injectors.
Based on drugs, the market is segmented into insulin derivatives, oral anti-diabetes drugs and non-insulin injectable anti-diabetes drugs. The insulin derivatives segment is further categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. The oral anti-diabetes drugs segment includes various drugs classes such as sulphonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors, GPP-4 inhibitors and SGLT-2 inhibitors. The non-insulin injectable anti-diabetes drugs segment is segmented into GLP-1 analogs and Pramlintide. The market for these devices and drugs has been extensively analyzed based on demand for branded and generic products in each class of drugs and devices. Rising prevalence of diabetic population across various regions of the world, pipeline products from each class, rising preference of patients and healthcare professionals toward technologically advanced monitoring and insulin delivery devices is driving the growth of the diabetes diagnostic devices and drugs market.
The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2013 to 2019, considering 2012 as the base year. The diabetes devices and drugs market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019.
Geographically, the diabetes diagnostic devices and drugs market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019, along with the CAGR (%) for the forecast period 2013 to 2019. The diabetes diagnostic devices and drugs market study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises a qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis and market attractiveness analysis. In addition, thorough analyses of various events, which occurred in the past five years and are expected to occur during forecast period, are also provided in the market overview section of the report. In this section, the major events, which affected the market and are expected to affect the market are studied. Further, value chain analysis (VCA) for drugs and devices is also provided, which highlights the major stages of the development of drugs and devices. The entire section of market overview plays an important role in understanding the market on a global level.
The diabetes devices and drugs market report also provides a highlight of the competitive landscape of the market wherein the market share analysis of the leading players in the diabetes devices and drugs market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the diabetes devices and drugs market such as Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Company Limited. Market players are profiled based on attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments.
The global diabetes devices and drugs market is segmented into the following categories:
Global Diabetes Devices Market, by Devices
Diabetes Monitoring and diagnostic devices
Insulin Delivery Devices
Global Diabetes Drugs Market, by Therapy
Oral anti-diabetes drugs class
Non-insulin injectable anti-diabetes drugs
Global Diabetes Drugs Market, by Geography
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote